Adlai Nortye Ltd. (NASDAQ:ANL - Get Free Report) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 4,300 shares, a growth of 38.7% from the October 31st total of 3,100 shares. Based on an average daily volume of 16,100 shares, the days-to-cover ratio is presently 0.3 days.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Adlai Nortye in a research note on Monday, November 11th.
Get Our Latest Analysis on Adlai Nortye
Adlai Nortye Trading Up 0.9 %
NASDAQ:ANL traded up $0.02 during trading hours on Friday, hitting $2.23. The company's stock had a trading volume of 1,954 shares, compared to its average volume of 11,709. Adlai Nortye has a 52-week low of $1.85 and a 52-week high of $17.48. The business's 50-day moving average is $2.27 and its two-hundred day moving average is $3.76.
Adlai Nortye Company Profile
(
Get Free Report)
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Adlai Nortye, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.
While Adlai Nortye currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
